The movement disorder society evidence-based medicine review update: Treatments for the motor symptoms of Parkinson's disease

Movement Disorders

Volumn 26, Issue SUPPL. 3, 2011, Pages

  Fox, Susan H ^a   Katzenschlager, Regina ^b   Lim, Shen Yang ^c   Ravina, Bernard ^d   Seppi, Klaus ^e   Coelho, Miguel ^f   Poewe, Werner ^e   Rascol, Olivier ^g   Goetz, Christopher G ^h   Sampaio, Cristina ^f  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b DANUBE HOSPITAL   (Austria)

^c UNIVERSITY OF MALAYA   (Malaysia)

^d UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^e UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^f INSTITUTO DE MEDICINA MOLECULAR JOÃO LOBO ANTUNES   (Portugal)

^g TOULOUSE UNIVERSITY HOSPITAL   (France)

^h RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acupuncture; Amantadine; Anticholinergics; Catechol O methyl transferase inhibitors; Clozapine; Deep brain stimulation; Dopamine agonists; Evidence based medicine; Exercise; Levodopa; Monoamine oxidase inhibitors; Neurosurgery; Occupational therapy; Parkinson's disease; Physical therapy; Speech therapy

Indexed keywords

AMANTADINE; APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CLOZAPINE; DIHYDROERGOCORNINE; ENTACAPONE; LEVODOPA; LEVODOPA METHYL ESTER; LISURIDE; PERGOLIDE; PIRIBEDIL; PLACEBO; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; ROTIGOTINE; SELEGILINE; SUMANIROLE; TOLCAPONE; ZONISAMIDE;

ACUPUNCTURE; AGRANULOCYTOSIS; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; APATHY; APPLICATION SITE DERMATITIS; APPLICATION SITE ERYTHEMA; APPLICATION SITE PRURITUS; ARTICLE; BRAIN DEPTH STIMULATION; CONSTIPATION; CONTROLLED RELEASE FORMULATION; DEEP HYPOTHERMIC CIRCULATORY ARREST; DIARRHEA; DIZZINESS; DRUG DOSAGE FORM COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; DYSKINESIA; EDEMA; EOSINOPHILIA; EVIDENCE BASED MEDICINE; FATIGUE; GASTROINTESTINAL SYMPTOM; GLOBUS PALLIDUS; HEART MUSCLE FIBROSIS; HUMAN; LOW DRUG DOSE; MONOTHERAPY; MOTOR DYSFUNCTION; NAUSEA; OCCUPATIONAL THERAPY; PAIN; PALLIDOTOMY; PARKINSON DISEASE; PATIENT SAFETY; PERIPHERAL EDEMA; PHYSIOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SOMNOLENCE; SPEECH THERAPY; SUBTHALAMIC NUCLEUS; SYMPTOMATOLOGY; THALAMOTOMY; TREATMENT OUTCOME; VALVULAR HEART DISEASE; VISUAL HALLUCINATION; VOMITING; WEIGHT REDUCTION;

ACUPUNCTURE THERAPY; ANTIPARKINSON AGENTS; DEEP BRAIN STIMULATION; EVIDENCE-BASED MEDICINE; FETAL STEM CELLS; HUMANS; MOTOR ACTIVITY; PALLIDOTOMY; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THALAMUS; TREATMENT OUTCOME;

EID: 80055083817     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23829     Document Type: Article

References (120)

1. Sackett DL, Straus S, Richardson S, Rosenberg W, Haynes RB. Evidence-Based Medicine: How to Practice and Teach EBM. 2nd ed. London, UK: Churchill Livingstone; 2000.
2. Montori VM, Guyatt GH. Progress in evidence-based medicine. JAMA 2008; 300: 1814-1816.
3. Goetz CG, Koller WC, Poewe W. Management of Parkinson's disease: an evidence-based review. Mov Disord 2002; 17( Suppl 4): S1-S166.
4. Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005; 20: 523-539.
5. Barone P, Lamb J, Ellis A, Clarke Z. Sumanirole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson's disease. Mov Disord 2007; 22: 483-489.
6. Bracco F, Battaglia A, Chouza C, et al. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs 2004; 18: 733-746.
7. Castro-Caldas A, Delwaide P, Jost W, et al. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease. Mov Disord 2006; 21: 500-509.
8. Deuschl G, Vaitkus A, Fox GC, Roscher T, Schremmer D, Gordin A. Efficacy and tolerability of Entacapone versus Cabergoline in parkinsonian patients suffering from wearing-off. Mov Disord 2007; 22: 1550-1555.
9. Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007; 22: 2398-2404.
10. Grosset K, Grosset D, Lees A. Trial of subtherapeutic pergolide in de novo Parkinson's disease. Mov Disord 2005; 20: 363-366.
11. Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005; 20: 190-199.
12. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004; 61: 1044-1053.
13. Katzenschlager R, Head J, Schrag A, Ben-Shlomo Y, Evans A, Lees AJ. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 2008; 71: 474-480.
14. LeWitt PA, Lyons KE, Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 2007; 68: 1262-1267.
15. Mizuno Y, Abe T, Hasegawa K, et al. Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study. Mov Disord 2007; 22: 1860-1865.
16. Moller JC, Oertel WH, Koster J, Pezzoli G, Provinciali L. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial. Mov Disord 2005; 20: 602-610.
17. Oertel WH, Wolters E, Sampaio C, et al. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study. Mov Disord 2006; 21: 343-353.
18. Pahwa R, Stacy MA, Factor SA, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 2007; 68: 1108-1115.
19. Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007; 6: 513-520.
20. Rascol O, Dubois B, Caldas AC, Senn S, Del Signore S, Lees A. Early piribedil monotherapy of Parkinson's disease: a planned seven-month report of the REGAIN study. Mov Disord 2006; 21: 2110-2115.
21. Singer C, Lamb J, Ellis A, Layton G. A comparison of sumanirole versus placebo or ropinirole for the treatment of patients with early Parkinson's disease. Mov Disord 2007; 22: 476-482.
22. Stocchi F, Hersh BP, Scott BL, Nausieda PA, Giorgi L. Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study. Curr Med Res Opin 2008; 24: 2883-2895.
23. Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007; 68: 272-276.
24. Watts RL, Lyons KE, Pahwa R, et al. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease. Mov Disord 2010; 25: 858-866.
25. Kieburtz K. Twice-daily, low-dose pramipexole in early Parkinson's disease: a randomized, placebo-controlled trial. Mov Disord 2011; 26: 37-44.
26. Hauser RA, Schapira AH, Rascol O, et al. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. Mov Disord 2010; 25: 2542-2549.
27. Trenkwalder C, Kies B, Rudzinska M, et al. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 2011; 26: 90-99.
28. Parkinson Study Group CALM Cohort Investigators. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol 2009; 66: 563-570.
29. Hauser RA, Rascol O, Korczyn AD, et al. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 2007; 22: 2409-2417.
30. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000; 342: 1484-1491.
31. Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010; 67: 589-595.
32. Voon V, Hassan K, Zurowski M, et al. Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology 2006; 66: 1750-1752.
33. Weintraub D, Siderowf AD, Potenza MN, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 2006; 63: 969-973.
34. Gallagher DA, O'Sullivan SS, Evans AH, Lees AJ, Schrag A. Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov Disord 2007; 22: 1757-1763.
35. Agarwal P, Fahn S, Frucht SJ. Diagnosis and management of pergolide-induced fibrosis. Mov Disord 2004; 19: 699-704.
36. Andersohn F, Garbe E. Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists. Mov Disord 2009; 24: 129-133.
37. Tan LC, Ng KK, Au WL, Lee RK, Chan YH, Tan NC. Bromocriptine use and the risk of valvular heart disease. Mov Disord 2009; 24: 344-349.
38. Simonis G, Fuhrmann JT, Strasser RH. Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists. Mov Disord 2007; 22: 1936-1942.
39. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351: 2498-2508.
40. Stocchi F, Fabbri L, Vecsei L, Krygowska-Wajs A, Monici Preti PA, Ruggieri SA. Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease. Clin Neuropharmacol 2007; 30: 18-24.
41. Stocchi F, Zappia M, Dall'Armi V, Kulisevsky J, Lamberti P, Obeso JA. Melevodopa/carbidopa effervescent formulation in the treatment of motor fluctuations in advanced Parkinson's disease. Mov Disord 2010; 25: 1881-1887.
42. Nyholm D, Nilsson Remahl AI, Dizdar N, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005; 64: 216-223.
43. Hauser RA, Panisset M, Abbruzzese G, Mancione L, Dronamraju N, Kakarieka A. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. Mov Disord 2009; 24: 541-550.
44. Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 2010; 68: 18-27.
45. Olanow CW, Kieburtz K, Stern M, et al. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch Neurol 2004; 61: 1563-1568.
46. Fung VS, Herawati L, Wan Y. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone. Mov Disord 2009; 24: 25-31.
47. Reichmann H, Boas J, Macmahon D, Myllyla V, Hakala A, Reinikainen K. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations. Acta Neurol Scand 2005; 111: 21-28.
48. Mizuno Y, Kanazawa I, Kuno S, Yanagisawa N, Yamamoto M, Kondo T. Placebo-controlled, double-blind dose-finding study of entacapone in fluctuating parkinsonian patients. Mov Disord 2007; 22: 75-80.
49. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005; 365: 947-954.
50. FDA. FDA Drug Safety Communication: Ongoing Safety Review of Stalevo (entacapone/carbidopa/levodopa) and possible development of Prostate Cancer. 2010. Accessed: October 30, 2010.
51. US Food and Drug Administration. FDA Drug Safety Communication: Ongoing Safety Review of Stalevo and possible increased cardiovascular risk. 2010. Accessed: December 15, 2010.
52. Lees AJ, Ratziu V, Tolosa E, Oertel WH. Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease. J Neurol Neurosurg Psychiatry 2007; 78: 944-948.
53. Palhagen S, Heinonen E, Hagglund J, Kaugesaar T, Maki-Ikola O, Palm R. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 2006; 66: 1200-1206.
54. Palhagen S, Heinonen EH, Hagglund J, et al. Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group. Neurology 1998; 51: 520-525.
55. Waters CH, Sethi KD, Hauser RA, Molho E, Bertoni JM. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord 2004; 19: 426-432.
56. Ondo WG, Sethi KD, Kricorian G. Selegiline orally disintegrating tablets in patients with Parkinson disease and "wearing off" symptoms. Clin Neuropharmacol 2007; 30: 295-300.
57. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004; 61: 561-566.
58. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009; 361: 1268-1278.
59. Stern MB, Marek KL, Friedman J, et al. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients. Mov Disord 2004; 19: 916-923.
60. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005; 62: 241-248.
61. Ferreira JJ, Neutel D, Mestre T, et al. Skin cancer and Parkinson's disease. Mov Disord 2010; 25: 139-148.
62. Wolf E, Seppi K, Katzenschlager R, et al. Long-term antidyskinetic efficacy of amantadine in Parkinson's disease. Mov Disord 2010; 25: 1357-1363.
63. Kubo S, Iwatake A, Ebihara N, Murakami A, Hattori N. Visual impairment in Parkinson's disease treated with amantadine: case report and review of the literature. Parkinsonism Relat Disord 2008; 14: 166-169.
64. Durif F, Debilly B, Galitzky M, et al. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 2004; 62: 381-388.
65. Fox SH, Chuang R, Brotchie JM. Serotonin and Parkinson's disease: on movement, mood, and madness. Mov Disord 2009; 24: 1255-1266.
66. Murata M, Hasegawa K, Kanazawa I. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology 2007; 68: 45-50.
67. Murata M. Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease. Curr Pharm Des 2004; 10: 687-693.
68. Anderson VC, Burchiel KJ, Hogarth P, Favre J, Hammerstad JP. Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson disease. Arch Neurol 2005; 62: 554-560.
69. Follett KA, Weaver FM, Stern M, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med 2010; 362: 2077-2091.
70. Esselink RA, de Bie RM, de Haan RJ, et al. Long-term superiority of subthalamic nucleus stimulation over pallidotomy in Parkinson disease. Neurology 2009; 73: 151-153.
71. Esselink RA, de Bie RM, de Haan RJ, et al. Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in Parkinson's disease: one year follow-up of a randomised observer-blind multi centre trial. Acta Neurochir (Wien) 2006; 148: 1247-1255; discussion 1255.
72. Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006; 355: 896-908.
73. Schupbach M, Gargiulo M, Welter ML, et al. Neurosurgery in Parkinson disease: a distressed mind in a repaired body? Neurology 2006; 66: 1811-1816.
74. Williams A, Gill S, Varma T, et al. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol 2010; 9: 581-591.
75. Weaver FM, Follett K, Stern M, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 2009; 301: 63-73.
76. Vitek JL, Bakay RA, Freeman A, et al. Randomized trial of pallidotomy versus medical therapy for Parkinson's disease. Ann Neurol 2003; 53: 558-569.
77. Schuurman PR, Bosch DA, Merkus MP, Speelman JD. Long-term follow-up of thalamic stimulation versus thalamotomy for tremor suppression. Mov Disord 2008; 23: 1146-1153.
78. Alvarez L, Macias R, Pavon N, et al. Therapeutic efficacy of unilateral subthalamotomy in Parkinson's disease: results in 89 patients followed for up to 36 months. J Neurol Neurosurg Psychiatry 2009; 80: 979-985.
79. Coban A, Hanagasi HA, Karamursel S, Barlas O. Comparison of unilateral pallidotomy and subthalamotomy findings in advanced idiopathic Parkinson's disease. Br J Neurosurg 2009; 23: 23-29.
80. Merello M, Tenca E, Perez Lloret S, et al. Prospective randomized 1-year follow-up comparison of bilateral subthalamotomy versus bilateral subthalamic stimulation and the combination of both in Parkinson's disease patients: a pilot study. Br J Neurosurg 2008; 22: 415-422.
81. Witt K, Daniels C, Reiff J, et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study. Lancet Neurol 2008; 7: 605-614.
82. Lim SY, Moro E, Lang AE. Non-motor symptoms of Parkinson's disease and the effects of deep brain stimulation. In: Chaudhuri KR, Tolosa E, Schapira A, Poewe W, eds. Non-Motor Symptoms of Parkinson's Disease. Oxford, UK: Oxford University Press; 2009: 339-352.
83. Klostermann F, Ehlen F, Vesper J, et al. Effects of subthalamic deep brain stimulation on dysarthrophonia in Parkinson's disease. J Neurol Neurosurg Psychiatry 2008; 79: 522-529.
84. Alberts JL, Voelcker-Rehage C, Hallahan K, Vitek M, Bamzai R, Vitek JL. Bilateral subthalamic stimulation impairs cognitive-motor performance in Parkinson's disease patients. Brain 2008; 131: 3348-3360.
85. Lim SY, O'Sullivan SS, Kotschet K, et al. Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease. J Clin Neurosci 2009; 16: 1148-1152.
86. Voon V, Krack P, Lang AE, et al. A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain 2008; 131: 2720-2728.
87. Drapier D, Drapier S, Sauleau P, et al. Does subthalamic nucleus stimulation induce apathy in Parkinson's disease? J Neurol 2006; 253: 1083-1091.
88. Barichella M, Marczewska AM, Mariani C, Landi A, Vairo A, Pezzoli G. Body weight gain rate in patients with Parkinson's disease and deep brain stimulation. Mov Disord 2003; 18: 1337-1340.
89. Macia F, Perlemoine C, Coman I, et al. Parkinson's disease patients with bilateral subthalamic deep brain stimulation gain weight. Mov Disord 2004; 19: 206-212.
90. Miyawaki E, Perlmutter JS, Troster AI, Videen TO, Koller WC. The behavioral complications of pallidal stimulation: a case report. Brain Cogn 2000; 42: 417-434.
91. Roane DM, Yu M, Feinberg TE, Rogers JD. Hypersexuality after pallidal surgery in Parkinson disease. Neuropsychiatry Neuropsychol Behav Neurol 2002; 15: 247-251.
92. Graff-Radford J, Foote KD, Rodriguez RL, et al. Deep brain stimulation of the internal segment of the globus pallidus in delayed runaway dyskinesia. Arch Neurol 2006; 63: 1181-1184.
93. Ellis T, de Goede CJ, Feldman RG, Wolters EC, Kwakkel G, Wagenaar RC. Efficacy of a physical therapy program in patients with Parkinson's disease: a randomized controlled trial. Arch Phys Med Rehabil 2005; 86: 626-632.
94. Ashburn A, Fazakarley L, Ballinger C, Pickering R, McLellan LD, Fitton C. A randomised controlled trial of a home based exercise programme to reduce the risk of falling among people with Parkinson's disease. J Neurol Neurosurg Psychiatry 2007; 78: 678-684.
95. Cakit BD, Saracoglu M, Genc H, Erdem HR, Inan L. The effects of incremental speed-dependent treadmill training on postural instability and fear of falling in Parkinson's disease. Clin Rehabil 2007; 21: 698-705.
96. Kurtais Y, Kutlay S, Tur BS, Gok H, Akbostanci C. Does treadmill training improve lower-extremity tasks in Parkinson disease? A randomized controlled trial. Clin J Sport Med 2008; 18: 289-291.
97. Tickle-Degnen L, Ellis T, Saint-Hilaire MH, Thomas CA, Wagenaar RC. Self-management rehabilitation and health-related quality of life in Parkinson's disease: a randomized controlled trial. Mov Disord 2010; 25: 194-204.
98. Ebersbach G, Ebersbach A, Edler D, et al. Comparing exercise in Parkinson's disease-the Berlin LSVT(R)BIG study. Mov Disord 2010; 25: 1902-1908.
99. Nieuwboer A, Kwakkel G, Rochester L, et al. Cueing training in the home improves gait-related mobility in Parkinson's disease: the RESCUE trial. J Neurol Neurosurg Psychiatry 2007; 78: 134-140.
100. Morris ME, Iansek R, Kirkwood B. A randomized controlled trial of movement strategies compared with exercise for people with Parkinson's disease. Mov Disord 2009; 24: 64-71.
101. Sage MD, Almeida QJ. Symptom and gait changes after sensory attention focused exercise vs aerobic training in Parkinson's disease. Mov Disord 2009; 24: 1132-1138.
102. Burini D, Farabollini B, Iacucci S, et al. A randomised controlled cross-over trial of aerobic training versus Qigong in advanced Parkinson's disease. Eura Medicophys 2006; 42: 231-238.
103. Schmitz-Hubsch T, Pyfer D, Kielwein K, Fimmers R, Klockgether T, Wullner U. Qigong exercise for the symptoms of Parkinson's disease: a randomized, controlled pilot study. Mov Disord 2006; 21: 543-548.
104. Hackney ME, Earhart GM. Tai Chi improves balance and mobility in people with Parkinson disease. Gait Posture 2008; 28: 456-460.
105. Allen NE, Canning CG, Sherrington C, et al. The effects of an exercise program on fall risk factors in people with Parkinson's disease: a randomized controlled trial. Mov Disord 2010; 25: 1217-1225.
106. Yang YR, Lee YY, Cheng SJ, Wang RY. Downhill walking training in individuals with Parkinson's disease: a randomized controlled trial. Am J Phys Med Rehabil 2010; 89: 706-714.
107. White DK, Wagenaar RC, Ellis TD, Tickle-Degnen L. Changes in walking activity and endurance following rehabilitation for people with Parkinson disease. Arch Phys Med Rehabil 2009; 90: 43-50.
108. Ramig LO, Sapir S, Fox C, Countryman S. Changes in vocal loudness following intensive voice treatment (LSVT) in individuals with Parkinson's disease: a comparison with untreated patients and normal age-matched controls. Mov Disord 2001; 16: 79-83.
109. Ramig LO, Sapir S, Countryman S, et al. Intensive voice treatment (LSVT) for patients with Parkinson's disease: a 2 year follow up. J Neurol Neurosurg Psychiatry 2001; 71: 493-498.
110. Huang W-Y, Xi G-F, Hua X-G. Clinical observation of combined acupuncture and herbs in treating Parkinson's disease. J Acupunct Tuina Sci 2009; 7: 33-36.
111. Goodwin VA, Richards SH, Taylor RS, Taylor AH, Campbell JL. The effectiveness of exercise interventions for people with Parkinson's disease: a systematic review and meta-analysis. Mov Disord 2008; 23: 631-640.
112. Keus SH, Munneke M, Nijkrake MJ, Kwakkel G, Bloem BR. Physical therapy in Parkinson's disease: evolution and future challenges. Mov Disord 2009; 24: 1-14.
113. Petzinger GM, Walsh JP, Akopian G, et al. Effects of treadmill exercise on dopaminergic transmission in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned mouse model of basal ganglia injury. J Neurosci 2007; 27: 5291-5300.
114. Deane KH, Whurr R, Playford ED, Ben-Shlomo Y, Clarke CE. A comparison of speech and language therapy techniques for dysarthria in Parkinson's disease. Cochrane Database Syst Rev 2001; 2: CD002814.
115. Suchowersky O, Gronseth G, Perlmutter J, Reich S, Zesiewicz T, Weiner WJ. Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66: 976-982.
116. Yorkston KM, Hakel M, Beukelman DR, Fager S. Evidence for effectiveness of treatment of loudness, rate, or prosody in dysarthria: a systematic review. J Med Speech Lang Pathol 2007; 15: xi-xxxvi.
117. Lee MS, Shin BC, Kong JC, Ernst E. Effectiveness of acupuncture for Parkinson's disease: a systematic review. Mov Disord 2008; 23: 1505-1515.
118. Stowe R, Ives N, Clarke CE, et al. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications. Cochrane Database Syst Rev 2010; 7: CD007166.
119. Stowe RL, Ives NJ, Clarke C, et al. Dopamine agonist therapy in early Parkinson's disease. Cochrane Database Syst Rev 2008; 2: CD006564.
120. Sox HC, Greenfield S. Comparative effectiveness research: a report from the Institute of Medicine. Ann Intern Med 2009; 151: 203-205.